“On April 16, 2019 the FDA ordered all manufacturers of surgical mesh intended for transvaginal repair of anterior compartment prolapse (cystocele) to stop selling and distributing their products immediately.” The full FDA report can be found here.
This is the just the next step in a long and ongoing process as the FDA evaluate the use of surgical mesh. Mesh in urological surgery is commonly used for three conditions:
-transvaginal mesh for pelvic organ prolapse
-transabdominal mesh for pelvic organ prolapse
-mesh sling to treat stress urinary incontinence
It is important to note that the recent FDA order only applies to the use of transvaginal mesh for pelvic organ prolapse and does not in any way change our practice of using mesh in other FDA situations. Further it should be noted that the FDA states that “Women who have received transvaginal mesh for the surgical repair of pelvic organ prolapse should continue with their annual and other routine check-ups and follow up care. There is no need to take additional action.”
I realize that not only are the treatment options available for the treatment of pelvic organ prolapse confusing but the recent FDA announcement further muddies the situation. While I do not treat pelvic organ prolapse in my surgical practice, I have numerous partners who are skilled in all of the treatment options available and if any patient has questions regarding their options, please contact my office for a consultation.